<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id>
<journal-title-group>
<journal-title>PLOS Computational Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1005455</article-id>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-16-01305</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Gene regulation</subject><subj-group><subject>MicroRNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>RNA</subject><subj-group><subject>Non-coding RNA</subject><subj-group><subject>MicroRNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Neoplasms</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive system</subject><subj-group><subject>Gastrointestinal tract</subject><subj-group><subject>Colon</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive system</subject><subj-group><subject>Gastrointestinal tract</subject><subj-group><subject>Colon</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Forecasting</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Forecasting</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject><subj-group><subject>Kidneys</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject><subj-group><subject>Kidneys</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Applied mathematics</subject><subj-group><subject>Algorithms</subject><subj-group><subject>Kernel methods</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Simulation and modeling</subject><subj-group><subject>Algorithms</subject><subj-group><subject>Kernel methods</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological parameters</subject><subj-group><subject>Body weight</subject><subj-group><subject>Obesity</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological parameters</subject><subj-group><subject>Body weight</subject><subj-group><subject>Obesity</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Blastomas</subject><subj-group><subject>Glioblastoma multiforme</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Neurological tumors</subject><subj-group><subject>Glioblastoma multiforme</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurological tumors</subject><subj-group><subject>Glioblastoma multiforme</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>PBMDA: A novel and effective path-based computational model for miRNA-disease association prediction</article-title>
<alt-title alt-title-type="running-head">miRNA-disease association prediction</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>You</surname>
<given-names>Zhu-Hong</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="fn" rid="econtrib001"><sup>‡</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9974-148X</contrib-id>
<name name-style="western">
<surname>Huang</surname>
<given-names>Zhi-An</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="fn" rid="econtrib001"><sup>‡</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Zhu</surname>
<given-names>Zexuan</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yan</surname>
<given-names>Gui-Ying</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Zheng-Wei</given-names>
</name>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wen</surname>
<given-names>Zhenkun</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9028-5342</contrib-id>
<name name-style="western">
<surname>Chen</surname>
<given-names>Xing</given-names>
</name>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Science, ürümqi, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>College of Computer Science and Software Engineering, Shenzhen University, Shenzhen, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, China</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>School of Computer Science and Technology, China University of Mining and Technology, Xuzhou, China</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>School of Information and Control Engineering, China University of Mining and Technology, Xuzhou, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Wang</surname>
<given-names>Edwin</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Calgary Cumming School of Medicine, CANADA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple"> <list-item><p><bold>Conceptualization:</bold> XC.</p></list-item> <list-item><p><bold>Data curation:</bold> XC ZAH.</p></list-item> <list-item><p><bold>Formal analysis:</bold> ZHY XC GYY.</p></list-item> <list-item><p><bold>Funding acquisition:</bold> XC ZZ GYY ZHY ZW.</p></list-item> <list-item><p><bold>Investigation:</bold> XC GYY ZWL.</p></list-item> <list-item><p><bold>Methodology:</bold> XC.</p></list-item> <list-item><p><bold>Project administration:</bold> XC ZZ.</p></list-item> <list-item><p><bold>Resources:</bold> XC.</p></list-item> <list-item><p><bold>Software:</bold> ZAH XC.</p></list-item> <list-item><p><bold>Supervision:</bold> XC ZZ.</p></list-item> <list-item><p><bold>Validation:</bold> XC ZAH ZHY.</p></list-item> <list-item><p><bold>Visualization:</bold> ZAH XC ZHY ZZ GYY ZWL.</p></list-item> <list-item><p><bold>Writing – original draft:</bold> ZAH XC ZHY.</p></list-item> <list-item><p><bold>Writing – review &amp; editing:</bold> XC ZAH ZZ.</p></list-item></list>
</p>
</fn>
<fn fn-type="other" id="econtrib001">
<p>‡ These authors are joint senior authors on this work.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">xingchen@amss.ac.cn</email> (XC); <email xlink:type="simple">zhuzx@szu.edu.cn</email> (ZZ)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2017</year>
</pub-date>
<volume>13</volume>
<issue>3</issue>
<elocation-id>e1005455</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>8</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>3</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>You et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pcbi.1005455"/>
<abstract>
<p>In the recent few years, an increasing number of studies have shown that microRNAs (miRNAs) play critical roles in many fundamental and important biological processes. As one of pathogenetic factors, the molecular mechanisms underlying human complex diseases still have not been completely understood from the perspective of miRNA. Predicting potential miRNA-disease associations makes important contributions to understanding the pathogenesis of diseases, developing new drugs, and formulating individualized diagnosis and treatment for diverse human complex diseases. Instead of only depending on expensive and time-consuming biological experiments, computational prediction models are effective by predicting potential miRNA-disease associations, prioritizing candidate miRNAs for the investigated diseases, and selecting those miRNAs with higher association probabilities for further experimental validation. In this study, <underline>P</underline>ath-<underline>B</underline>ased <underline>M</underline>iRNA-<underline>D</underline>isease <underline>A</underline>ssociation (PBMDA) prediction model was proposed by integrating known human miRNA-disease associations, miRNA functional similarity, disease semantic similarity, and Gaussian interaction profile kernel similarity for miRNAs and diseases. This model constructed a heterogeneous graph consisting of three interlinked sub-graphs and further adopted depth-first search algorithm to infer potential miRNA-disease associations. As a result, PBMDA achieved reliable performance in the frameworks of both local and global LOOCV (AUCs of 0.8341 and 0.9169, respectively) and 5-fold cross validation (average AUC of 0.9172). In the cases studies of three important human diseases, 88% (Esophageal Neoplasms), 88% (Kidney Neoplasms) and 90% (Colon Neoplasms) of top-50 predicted miRNAs have been manually confirmed by previous experimental reports from literatures. Through the comparison performance between PBMDA and other previous models in case studies, the reliable performance also demonstrates that PBMDA could serve as a powerful computational tool to accelerate the identification of disease-miRNA associations.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>Identification of miRNA-disease associations is considered as a key way for the development of pathology, diagnose and therapy. Computational prediction models contribute to discovering the underlying disease-related miRNAs on a large scale. Based on the assumption that functionally related miRNAs tend to be involved in phenotypically similar disease and vice versa, the model of PBMDA was developed to prioritize the underlying miRNA-disease associations by adopting a special depth-first search algorithm in a heterogeneous graph, which was composed of known miRNA-disease association network, miRNA similarity network, and disease similarity network. Through leave-one-out cross validation and 5-fold cross validation, the promising results demonstrated the effectiveness of the proposed model. We further implemented the case studies of three important human complex diseases, 88%, 88% and 90% of top-50 predicted miRNA-disease associations have been manually confirmed based on recent experimental reports. It is anticipated that PBMDA could prioritize the most potential miRNA-disease associations on a large scale for advancing the progress of biological experiment validation in the future, which could further contribute to the understanding of complex disease mechanisms.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>11301517</award-id>
<principal-award-recipient>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9028-5342</contrib-id>
<name name-style="western">
<surname>Chen</surname>
<given-names>Xing</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>61471246</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhu</surname>
<given-names>Zexuan</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>Guangdong Foundation of Outstanding Young Teachers in Higher Education Institutions</institution>
</funding-source>
<award-id>Yq2013141</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhu</surname>
<given-names>Zexuan</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution>Guangdong Special Support Program of Top-notch Young Professionals</institution>
</funding-source>
<award-id>2014TQ01X273</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhu</surname>
<given-names>Zexuan</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>11371355</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Yan</surname>
<given-names>Gui-Ying</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>61572506</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>You</surname>
<given-names>Zhu-Hong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution>Pioneer Hundred Talents Program of Chinese Academy of Sciences</institution>
</funding-source>
<principal-award-recipient>
<name name-style="western">
<surname>You</surname>
<given-names>Zhu-Hong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award008">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>11631014</award-id>
<principal-award-recipient>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9028-5342</contrib-id>
<name name-style="western">
<surname>Chen</surname>
<given-names>Xing</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award009">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>11631014</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Yan</surname>
<given-names>Gui-Ying</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award010">
<funding-source>
<institution>National Nature Science Foundation of China</institution>
</funding-source>
<award-id>61572328</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Wen</surname>
<given-names>Zhenkun</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award011">
<funding-source>
<institution>Research funding of China-UK Visual Information Processing Lab</institution>
</funding-source>
<principal-award-recipient>
<name name-style="western">
<surname>Wen</surname>
<given-names>Zhenkun</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>XC was supported by National Natural Science Foundation of China under Grant No. 11301517 and 11631014. ZZ was supported by the National Natural Science Foundation of China under Grant No. 61471246, Guangdong Foundation of Outstanding Young Teachers in Higher Education Institutions under Grant No. Yq2013141, and Guangdong Special Support Program of Top-notch Young Professionals under Grant No. 2014TQ01X273. GYY was supported by National Natural Science Foundation of China under Grant No. 11371355 and 11631014. ZHY was supported by National Natural Science Foundation of China under Grant No. 61572506. ZW was supported by National Nature Science Foundation of China under Grant No. 61572328 and research funding of China-UK Visual Information Processing Lab. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="11"/>
<page-count count="22"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>PLOS Publication Stage</meta-name>
<meta-value>vor-update-to-uncorrected-proof</meta-value>
</custom-meta>
<custom-meta>
<meta-name>Publication Update</meta-name>
<meta-value>2017-04-07</meta-value>
</custom-meta>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>MicroRNAs (miRNAs) are an abundant class of small (20~25 nucleotides) endogenous non-coding RNAs, which were normally deemed as negative gene regulators by suppressing the expression of messenger RNAs (mRNAs) in a sequence-specific manner and repressing the protein translation of their target genes [<xref ref-type="bibr" rid="pcbi.1005455.ref001">1</xref>–<xref ref-type="bibr" rid="pcbi.1005455.ref004">4</xref>]. Since the two members of the miRNA family (i.e., <italic>lin-4</italic> and <italic>let-7</italic>) were firstly discovered [<xref ref-type="bibr" rid="pcbi.1005455.ref005">5</xref>–<xref ref-type="bibr" rid="pcbi.1005455.ref007">7</xref>], mounting biological observations and studies have indicated that miRNAs play important roles in many important biological processes. To date, 2588 miRNAs have been discovered in the human genome [<xref ref-type="bibr" rid="pcbi.1005455.ref008">8</xref>]. With the advances in molecular biology and biotechnology, miRNAs have been proven to influence many important physiological processes such as cell growth [<xref ref-type="bibr" rid="pcbi.1005455.ref009">9</xref>], immune reaction [<xref ref-type="bibr" rid="pcbi.1005455.ref010">10</xref>], cell differentiation [<xref ref-type="bibr" rid="pcbi.1005455.ref011">11</xref>], cell development [<xref ref-type="bibr" rid="pcbi.1005455.ref009">9</xref>], cell cycle regulation [<xref ref-type="bibr" rid="pcbi.1005455.ref012">12</xref>], inflammation [<xref ref-type="bibr" rid="pcbi.1005455.ref013">13</xref>], cell apoptosis [<xref ref-type="bibr" rid="pcbi.1005455.ref014">14</xref>], stress response [<xref ref-type="bibr" rid="pcbi.1005455.ref009">9</xref>,<xref ref-type="bibr" rid="pcbi.1005455.ref015">15</xref>], and tumor invasion [<xref ref-type="bibr" rid="pcbi.1005455.ref016">16</xref>]. In addition, emerging evidences imply the strong links between miRNAs and diseases. For examples, <italic>miR-129</italic>, <italic>miR-142-5p</italic>, and <italic>miR-25</italic> were found to be differentially expressed in all pediatric brain tumor types [<xref ref-type="bibr" rid="pcbi.1005455.ref017">17</xref>]. <italic>MiR-145</italic> was observed to target the insulin receptor substrate-1 and restrain the growth of colon cancer cells [<xref ref-type="bibr" rid="pcbi.1005455.ref018">18</xref>]. <italic>MiR-23/27/24</italic> clusters were involved in angiogenesis and endothelial apoptosis, which has potential therapeutic applications in both of vascular disorders and ischemic heart disease [<xref ref-type="bibr" rid="pcbi.1005455.ref019">19</xref>]. Therefore, the accumulating miRNA-disease associations could be utilized for the pathological classification, individualized diagnosis, and disease treatment [<xref ref-type="bibr" rid="pcbi.1005455.ref020">20</xref>].</p>
<p>Some databases (e.g. HMDD [<xref ref-type="bibr" rid="pcbi.1005455.ref021">21</xref>] and miR2Disease [<xref ref-type="bibr" rid="pcbi.1005455.ref022">22</xref>]) have been constructed for providing accumulating insights into the relationship between miRNAs and diseases. To date, HMDD has already collected 10368 entries including 572 miRNAs and 378 diseases, which shed some light on the molecular mechanisms of diseases. The existing knowledge of miRNA-disease associations mainly comes from previous biological experiments. However, only depending on the traditional biological experiments is time-consuming and costly, therefore unpractical to detect miRNA-disease associations on a large scale in a short term. For addressing these challenges, increasing attentions have been devoted to developing computational models to predict potential miRNA-disease associations by integrating various experimentally confirmed and heterogeneous datasets [<xref ref-type="bibr" rid="pcbi.1005455.ref023">23</xref>–<xref ref-type="bibr" rid="pcbi.1005455.ref029">29</xref>].</p>
<p>For predicting or prioritizing disease-related miRNAs, there have been some computational methods proposed, which are mostly based on the assumption that functionally related miRNAs tend to be involved in phenotypically similar diseases and vice versa. For examples, Jiang <italic>et al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref030">30</xref>] constructed functionally related miRNA network and human phenome-microRNAome network and prioritized the potential miRNA-disease associations according to the cumulative hypergeometric distribution. However, this method excessively depended on the predicted miRNA-target associations which include a high rate of false-positive and high false-negative results. Xuan <italic>et al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref031">31</xref>] presented the prediction model of HDMP based on the most weighted similar neighbors to predict potential disease-associated miRNAs. This method integrated the information content of disease terms and phenotype similarity between diseases to infer the functional similarity of miRNA pairs. However, it becomes invalid when no known associated miRNA is available for diseases which are less investigated. Mørk <italic>et al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref032">32</xref>] developed a protein-driven method called miRPD for inferring miRNA-disease associations by calculating the product of the two scoring functions, which were calculated based on the miRNA-protein and protein-disease associations. These three aforementioned methods only considered miRNA neighbor information in their ranking system, which can be summarized as traditional local network similarity measure-based computational models. Some methods were mainly proposed based on the more effective global network similarity measure rather than traditional local network similarity measures. For example, Chen <italic>et al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref033">33</xref>] proposed the computational model of <underline>R</underline>andom <underline>W</underline>alk with <underline>R</underline>estart for <underline>M</underline>iRNA-<underline>D</underline>isease <underline>A</underline>ssociation (RWRMDA) to identify novel disease-related miRNAs by implementing random walks on the miRNA-miRNA functional similarity network. However, this model cannot work for new diseases without any known related miRNAs. Similarly, Xuan <italic>et</italic>.<italic>al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref034">34</xref>] developed a computational model of <underline>MI</underline>RNAs associated with <underline>D</underline>iseases <underline>P</underline>rediction (MIDP) and its extension version named MIDPE for the diseases with known related miRNAs and without any known related miRNAs, respectively. They established the transition matrices between the labeled and unlabeled nodes for exploring the prior information of nodes and the different ranges of topologies. Shi <italic>et</italic>.<italic>al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref035">35</xref>] also performed random walk analysis to explore the relationships between miRNAs and diseases by calculating the functional associations between miRNA targets and disease genes in protein-protein interaction networks. Later, Chen <italic>et al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref036">36</xref>] developed the method of <underline>W</underline>ithin and <underline>B</underline>etween <underline>S</underline>core for <underline>M</underline>iRNA-<underline>D</underline>isease <underline>A</underline>ssociation prediction (WBSMDA) to uncover the potential miRNA-disease associations by integrating several heterogeneous biological datasets, which improves the prediction accuracy of previous classical computational models. By calculating and combining Within-Score and Between-Score, WBSMDA can work for new diseases without any known related miRNAs and new miRNAs without associated diseases. Some proposed machine learning-based models demonstrated their power in this field. Based on the assumption that aberrant regulations of target mRNAs occur because their miRNAs are implicated in a specific disease, Xu <italic>et al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref037">37</xref>] prioritized novel disease-related miRNAs by constructing the <underline>M</underline>iRNA <underline>T</underline>arget-<underline>D</underline>ysregulated <underline>N</underline>etwork (MTDN). In addition, they built a support vector machine (SVM) based supervised classifier to distinguish prostate cancer and non-prostate cancer related miRNAs by combining four topological features extracted from MTDN. However, the prediction performance suffered from unavailable verified negative miRNA-disease association samples. A semi-supervised method called <underline>R</underline>egularized <underline>L</underline>east <underline>S</underline>quares for <underline>M</underline>iRNA-<underline>D</underline>isease <underline>A</underline>ssociation (RLSMDA) was developed by Chen <italic>et al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref038">38</xref>]. Considering obtaining verified negative samples (i.e. those disease-miRNA pairs without any known association evidences) is difficult and even impossible, cost functions were defined and minimized in the framework of Regularized Least Squares (RLS). Then the optimal classifiers in the disease and miRNA spaces were yielded and combined to obtain the final predictive results. Chen <italic>et al</italic>. [<xref ref-type="bibr" rid="pcbi.1005455.ref039">39</xref>] also developed the model of Restricted Boltzmann Machine (RBM) for multiple types of miRNA-disease association prediction (RBMMMDA) for predicting various types of miRNA-disease associations. Based on the known miRNA-disease association network, RBMs were constructed and trained by Contrastive Divergence (CD) algorithm. Finally, this model implemented prediction by calculating conditional probabilities.</p>
<p>The knowledge on miRNAs provides valuable information for the prevention, diagnosis and treatment of human diseases. There is an urgent need to accelerate the identification of disease-miRNA associations for further studies on pathology as well as drug development. We here proposed a novel <underline>P</underline>ath-<underline>B</underline>ased <underline>M</underline>iRNA-<underline>D</underline>isease <underline>A</underline>ssociation (PBMDA) prediction method by constructing a heterogeneous graph consisting of three interlinked sub-graphs (i.e., miRNA-miRNA similarity network, disease-disease similarity network and known miRNA-disease association network). Integrating different types of heterogeneous biological datasets allows that PBMDA could be applied to the new diseases with no known associated miRNAs and the new miRNAs with no known associated diseases. In addition, the proposed method can simultaneously prioritize all unknown miRNAs for all the investigated diseases.</p>
<p>In this work, three evaluation frameworks, including global leave-one-out cross validation (global LOOCV), local leave-one-out cross validation (local LOOCV) and 5-fold cross validation (5-fold CV), were implemented to evaluate the prediction performance of PBMDA. When performing on the HMDD database, PBMDA obtained the best performance in the frameworks of both local and global LOOCV (AUCs of 0.8341 and 0.9169, respectively) and 5-fold cross validation (average AUC of 0.9172) compared with several state-of-the-art computational models [<xref ref-type="bibr" rid="pcbi.1005455.ref031">31</xref>,<xref ref-type="bibr" rid="pcbi.1005455.ref033">33</xref>,<xref ref-type="bibr" rid="pcbi.1005455.ref036">36</xref>]. To further evaluate the performance of PBMDA, we implemented case studies of three important human diseases. As a result, most of top-50 predicted disease-related miRNAs (44/50 for <italic>Esophageal Neoplasms</italic>; 44/50 for <italic>Kidney Neoplasms</italic>; 45/50 for <italic>Colon Neoplasms</italic>) were verified by previously published literatures, respectively. Besides, 9 out of top-10 predicted obesity-related were manually validated based on the published literatures. Our model also represents an improvement to the prediction accuracy through the comparison performance between PBMDA and other previous representative models in case studies. A simulation experiment also proves the applicability of our model to a new disease (no known associated miRNAs).</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Human miRNA-disease associations</title>
<p>HMDD database (<ext-link ext-link-type="uri" xlink:href="http://www.cuilab.cn/hmdd" xlink:type="simple">http://www.cuilab.cn/hmdd</ext-link>) has collected 5430 experimentally verified human miRNA-disease associations (see <xref ref-type="supplementary-material" rid="pcbi.1005455.s001">S1 Table</xref>), involving 495 miRNAs and 383 diseases (see <xref ref-type="supplementary-material" rid="pcbi.1005455.s002">S2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1005455.s003">S3</xref> Tables). The adjacency matrix <italic>Y</italic> is constructed to describe the confirmed associations between miRNA and disease. Namely, if miRNA <italic>m</italic>(<italic>i</italic>) is recorded to be associated with disease <italic>d</italic>(<italic>j</italic>), the entity <italic>Y</italic>(<italic>i</italic>,<italic>j</italic>) is equal to 1, otherwise 0. For further description in detail, the investigated numbers of miRNAs and diseases in our study are represented by variables <italic>nm</italic> and <italic>nd</italic>, respectively. To evaluate the prediction lists for case studies, another two independent databases (i.e. dbDEMC [<xref ref-type="bibr" rid="pcbi.1005455.ref040">40</xref>] and miR2Disease [<xref ref-type="bibr" rid="pcbi.1005455.ref022">22</xref>]) are utilized for validation.</p>
</sec>
<sec id="sec004">
<title>MiRNA functional similarity</title>
<p>According to previous literature [<xref ref-type="bibr" rid="pcbi.1005455.ref041">41</xref>], it could be concluded that miRNAs with similar functions are more likely associated with similar diseases. Under this assumption, miRNA functional similarity score was calculated (<ext-link ext-link-type="uri" xlink:href="http://www.cuilab.cn/files/images/cuilab/misim.zip" xlink:type="simple">http://www.cuilab.cn/files/images/cuilab/misim.zip</ext-link>). We therefore utilized these data to construct miRNA functional similarity symmetric matrix <italic>FS</italic> (see <xref ref-type="supplementary-material" rid="pcbi.1005455.s004">S4 Table</xref>), in which the entity <italic>FS</italic>(<italic>m</italic>(<italic>i</italic>),<italic>m</italic>(<italic>j</italic>)) indicates how is miRNA <italic>m</italic>(<italic>i</italic>) functionally similar to another miRNA <italic>m</italic>(<italic>j</italic>).</p>
</sec>
<sec id="sec005">
<title>Disease semantic similarity</title>
<p>Mesh database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/" xlink:type="simple">http://www.ncbi.nlm.nih.gov/</ext-link>), a strict system for disease classification, is available for effectively researching the relationship between different diseases. Disease could be transformed into corresponding Directed Acyclic Graph (DAG), such as <italic>DAG</italic>(<italic>D</italic>) = (<italic>T</italic>(<italic>D</italic>),<italic>E</italic>(<italic>D</italic>)), where <italic>T(D)</italic> indicates the node set including node <italic>D</italic> and its ancestor nodes, and <italic>E</italic>(<italic>D</italic>) is the edge set of corresponding direct links from a parent node to a child node, which represents the relationship between different diseases [<xref ref-type="bibr" rid="pcbi.1005455.ref041">41</xref>]. Based on disease DAG, the contribution of disease term <italic>d</italic> to the semantic value of disease <italic>D</italic> and the semantic value of disease <italic>D</italic> itself can be formulated by the following two equations, respectively.
<disp-formula id="pcbi.1005455.e001">
<alternatives>
<graphic id="pcbi.1005455.e001g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e001" xlink:type="simple"/>
<mml:math display="block" id="M1">
<mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mi>D</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mspace width="15em"/><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.5em"/><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mi>D</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>D</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">max</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>*</mml:mo></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo>'</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>|</mml:mo><mml:mi>d</mml:mi><mml:mo>'</mml:mo><mml:mo>∈</mml:mo><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.25em"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.25em"/><mml:mi>d</mml:mi></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mspace width="1em"/><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.5em"/><mml:mi>d</mml:mi><mml:mo>≠</mml:mo><mml:mi>D</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
<label>(1)</label>
</disp-formula>
<disp-formula id="pcbi.1005455.e002">
<alternatives>
<graphic id="pcbi.1005455.e002g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e002" xlink:type="simple"/>
<mml:math display="block" id="M2">
<mml:mrow><mml:mi>D</mml:mi><mml:mi>V</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>D</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mo>∈</mml:mo><mml:mi>T</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>D</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:mrow>
</mml:math>
</alternatives>
<label>(2)</label>
</disp-formula>
Where △ is a the semantic contribution decay factor, which shows that as the distances between disease <italic>D</italic> and its ancestor diseases increases, their contribution to the semantic value of disease <italic>D</italic> progressively decreases. Accordingly, disease <italic>D</italic> locates in the 0th layer, the contribution to the semantic value of disease <italic>D</italic> itself was defined as 1. The contribution of its ancestor disease should be multiplied by the semantic contribution decay factor. Therefore, △ should be assigned a value between 0 and 1, and that this value was set as 0.5 here according to some previous important literatures [<xref ref-type="bibr" rid="pcbi.1005455.ref042">42</xref>,<xref ref-type="bibr" rid="pcbi.1005455.ref043">43</xref>]. Based on this way to measure disease semantic similarity, it should be considered that two diseases sharing more common parts of their DAGs should obtain higher semantic similarity. Under this assumption, the semantic similarity between two diseases <italic>d</italic>(<italic>i</italic>) and <italic>d</italic>(<italic>j</italic>) can be calculated as:
<disp-formula id="pcbi.1005455.e003">
<alternatives>
<graphic id="pcbi.1005455.e003g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e003" xlink:type="simple"/>
<mml:math display="block" id="M3">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>∈</mml:mo><mml:mi>T</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>∩</mml:mo><mml:mi>T</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>V</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>V</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow>
</mml:math>
</alternatives>
<label>(3)</label>
</disp-formula>
where the entity <italic>SS</italic>(<italic>d</italic>(<italic>i</italic>),<italic>d</italic>(<italic>j</italic>)) in row <italic>i</italic> column <italic>j</italic> represents the disease semantic similarity between <italic>d</italic>(<italic>i</italic>) and <italic>d</italic>(<italic>j</italic>).</p>
</sec>
<sec id="sec006">
<title>Gaussian interaction profile kernel similarity for diseases</title>
<p>According to the basic assumption that two miRNAs with more functional similarity tend to be more associated with similar diseases, the topologic information of the known miRNA-disease association network could be used to measure disease similarity. We therefore introduce Gaussian interaction profile kernel for calculating the network topologic similarity between diseases. A binary vector <italic>IP</italic>(<italic>d</italic>(<italic>i</italic>)), i.e. the <italic>ith</italic> column of matrix <italic>Y</italic>, is recorded as the interaction profiles of disease <italic>d</italic>(<italic>i</italic>) for representing associations between <italic>d</italic>(<italic>i</italic>) itself and each miRNA. We then utilized Eq (<xref ref-type="disp-formula" rid="pcbi.1005455.e004">4</xref>) to compute Gaussian kernel similarity between disease <italic>d</italic>(<italic>i</italic>) and disease <italic>d</italic>(<italic>j</italic>) based on their interaction profiles.
<disp-formula id="pcbi.1005455.e004">
<alternatives>
<graphic id="pcbi.1005455.e004g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e004" xlink:type="simple"/>
<mml:math display="block" id="M4">
<mml:mrow><mml:mi>K</mml:mi><mml:mi>D</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi mathvariant="normal">exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>‖</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
<label>(4)</label>
</disp-formula>
where parameter <italic>γ</italic><sub><italic>d</italic></sub> is a regulation parameter of the kernel bandwidth. As a symmetric matrix, <italic>KD</italic> represents the Gaussian interaction profile kernel similarity for all investigated diseases. Parameter <italic>γ</italic><sub><italic>d</italic></sub> is needed to be updated by using a new bandwidth parameter <italic>γ</italic><sup>'</sup><sub><italic>d</italic></sub> divided by the average value of associations with miRNAs for all diseases. Based on the previous successful research about lncRNA-disease association prediction [<xref ref-type="bibr" rid="pcbi.1005455.ref044">44</xref>], <italic>γ</italic><sup>'</sup><sub><italic>d</italic></sub> is set to 1 for controlling the kernel bandwidth. So <italic>γ</italic><sub><italic>d</italic></sub> can be formulated as:
<disp-formula id="pcbi.1005455.e005">
<alternatives>
<graphic id="pcbi.1005455.e005g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e005" xlink:type="simple"/>
<mml:math display="block" id="M5">
<mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mo>'</mml:mo></mml:msup><mml:msub><mml:mrow/><mml:mi>d</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>‖</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
<label>(5)</label>
</disp-formula></p>
</sec>
<sec id="sec007">
<title>Gaussian interaction profile kernel similarity for miRNAs</title>
<p>Similarly, we also calculated the Gaussian interaction profile kernel similarity for miRNAs, which can be calculated by Eqs (<xref ref-type="disp-formula" rid="pcbi.1005455.e006">6</xref>) and (<xref ref-type="disp-formula" rid="pcbi.1005455.e007">7</xref>):
<disp-formula id="pcbi.1005455.e006">
<alternatives>
<graphic id="pcbi.1005455.e006g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e006" xlink:type="simple"/>
<mml:math display="block" id="M6">
<mml:mrow><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>‖</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
<label>(6)</label>
</disp-formula>
<disp-formula id="pcbi.1005455.e007">
<alternatives>
<graphic id="pcbi.1005455.e007g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e007" xlink:type="simple"/>
<mml:math display="block" id="M7">
<mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mo>'</mml:mo></mml:msup><mml:msub><mml:mrow/><mml:mi>m</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>n</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>‖</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
<label>(7)</label>
</disp-formula>
where <italic>γ</italic><sup>'</sup><sub><italic>m</italic></sub> = 1 and <italic>KM</italic> is a symmetric matrix, whose entity <italic>KM</italic>(<italic>m</italic>(<italic>i</italic>),<italic>m</italic>(<italic>j</italic>)) denotes the Gaussian interaction profile kernel similarity between miRNA <italic>m</italic>(<italic>i</italic>) and miRNA <italic>m</italic>(<italic>j</italic>).</p>
</sec>
<sec id="sec008">
<title>Integrated similarity for miRNA and disease</title>
<p>MiRNA functional similarity and disease semantic similarity are the primary data to construct the disease and miRNA similarity matrix. However, these matrices have the problem of sparsity, so we calculated the Gaussian interaction profile kernel similarity based on the known miRNA-disease associations for calculating the similarity of those disease-disease or miRNA-miRNA pairs without corresponding disease semantic similarity or miRNA functional similarity. For constructing two integrated similarity matrix (i.e., miRNA similarity matrix <italic>S</italic><sub><italic>m</italic></sub> and disease similarity matrix <italic>S</italic><sub><italic>d</italic></sub>), we integrated miRNA functional similarity, disease semantic similarity, and Gaussian interaction profile kernel similarity for miRNAs and diseases by judging whether miRNA <italic>m</italic>(<italic>i</italic>)/disease <italic>d</italic>(<italic>i</italic>) has functional/semantic similarity with another miRNA <italic>m</italic>(<italic>j</italic>)/disease <italic>d</italic>(<italic>j</italic>) or not.</p>
<disp-formula id="pcbi.1005455.e008">
<alternatives>
<graphic id="pcbi.1005455.e008g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e008" xlink:type="simple"/>
<mml:math display="block" id="M8">
<mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>F</mml:mi><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="2em"/><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.25em"/><mml:mtext>m</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.25em"/><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.25em"/><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="8em"/><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
<label>(8)</label>
</disp-formula>
<disp-formula id="pcbi.1005455.e009">
<alternatives>
<graphic id="pcbi.1005455.e009g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e009" xlink:type="simple"/>
<mml:math display="block" id="M9">
<mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>S</mml:mi><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="2em"/><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.25em"/><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.25em"/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mspace width="0.25em"/><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>K</mml:mi><mml:mi>D</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="8em"/><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
<label>(9)</label>
</disp-formula>
</sec>
<sec id="sec009">
<title>PBMDA</title>
<p>For prioritizing the most possible potential miRNA-disease associations, we here devised a novel <underline>P</underline>ath-<underline>B</underline>ased <underline>M</underline>iRNA-<underline>D</underline>isease <underline>A</underline>ssociation (PBMDA) prediction method (See <xref ref-type="fig" rid="pcbi.1005455.g001">Fig 1</xref>). For eliminating the node sets with the weak interaction, we set the threshold variable <bold><italic>T</italic></bold> to 0.5 based on the previous literature research [<xref ref-type="bibr" rid="pcbi.1005455.ref045">45</xref>], which means we did not take such links into consideration if the similarity between these nodes was less than 0.5. So that three weighted matrixes can be represented as:</p>
<fig id="pcbi.1005455.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flowchart of PBMDA.</title>
<p>Three networks were integrated to construct a heterogeneous graph and the potential miRNA-disease associations could be effectively inferred by the scoring system.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.g001" xlink:type="simple"/>
</fig>
<disp-formula id="pcbi.1005455.e010">
<alternatives>
<graphic id="pcbi.1005455.e010g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e010" xlink:type="simple"/>
<mml:math display="block" id="M10">
<mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi><mml:mi>N</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi><mml:mi>N</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mspace width="10em"/><mml:msub><mml:mi>S</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mi>T</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>S</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="6.5em"/><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mspace width="9.75em"/><mml:msub><mml:mi>S</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mi>T</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>S</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="7em"/><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi><mml:mi>N</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>Y</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="7em"/><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:mi>n</mml:mi><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>j</mml:mi><mml:mo>≤</mml:mo><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr></mml:mtable>
</mml:math>
</alternatives>
<label>(10)</label>
</disp-formula>
<p>In this way, we constructed a heterogeneous graph with lots of paths, which consisted of these three weighted matrixes. A path was defined as a connection between a miRNA and a disease. Furthermore, all paths between a miRNA and a disease must be acyclic to avoid the visited nodes from being traversed repeatedly. A specific depth-first search algorithm was adopted to traverse all paths in the graph, which is easy to be implemented as a recursive algorithm. For saving time, we set a parameter <bold><italic>L</italic></bold> to limit the maximum length of paths. According to previous literature research [<xref ref-type="bibr" rid="pcbi.1005455.ref045">45</xref>] and comparison experiments, we found that it was suitable to set <bold><italic>L</italic></bold> = 3 after trying different values from 2 to 4 increasingly, i.e. one path was not allowed to include more than three edges. Based on the assumption that if more paths are found to connect a miRNA and a disease, they are more likely to have associations, the accumulative contributions from all paths between a miRNA-disease pair could be integrated as a final score. Accordingly, the scoring formula can be defined as Eq (<xref ref-type="disp-formula" rid="pcbi.1005455.e011">11</xref>) with the exponential decay function <italic>F</italic><sub><italic>decay</italic></sub>(<italic>p</italic>), which is depended on the path between a specific miRNA <italic>m</italic><sub><italic>i</italic></sub> and a specific disease d<sub>j</sub>:
<disp-formula id="pcbi.1005455.e011">
<alternatives>
<graphic id="pcbi.1005455.e011g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e011" xlink:type="simple"/>
<mml:math display="block" id="M11">
<mml:mrow><mml:munder><mml:mrow><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:mi>n</mml:mi><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>j</mml:mi><mml:mo>≤</mml:mo><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:munder><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>w</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>∏</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>w</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>w</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow>
</mml:math>
</alternatives>
<label>(11)</label>
</disp-formula>
where <italic>p</italic> = {<italic>p</italic><sub>1</sub>,<italic>p</italic><sub>2</sub>,…,<italic>p</italic><sub><italic>n</italic></sub>} is a set of paths linking up a miRNA <italic>m</italic><sub><italic>i</italic></sub> and a disease d<sub>j</sub>, and ∏<italic>p</italic><sub><italic>w</italic></sub> represents the product of the weight of the all the edges in path <italic>p</italic><sub><italic>w</italic></sub> obtained from the Eq (<xref ref-type="disp-formula" rid="pcbi.1005455.e010">10</xref>).</p>
<p>Generally, longer paths between a miRNA and a disease should have less confidence to directly demonstrate their relationship, i.e. the contributions from the longer path should be cut down more sharply. So the decay function <italic>F</italic><sub><italic>decay</italic></sub>(<italic>p</italic>) can be calculated as follows:
<disp-formula id="pcbi.1005455.e012">
<alternatives>
<graphic id="pcbi.1005455.e012g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e012" xlink:type="simple"/>
<mml:math display="block" id="M12">
<mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>p</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>×</mml:mo><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(12)</label>
</disp-formula>
where parameter <italic>α</italic> is a decay factor, which was set 2.26, according to previous literature research [<xref ref-type="bibr" rid="pcbi.1005455.ref045">45</xref>], and <italic>len</italic>(<italic>p</italic>) is the length of path <italic>p</italic>. After traversing all paths in the graph, each miRNA-disease pair could obtain a final score representing the association confidence between this miRNA and disease, i.e. the higher score they obtain, the more closely related they should be. As an example in <xref ref-type="fig" rid="pcbi.1005455.g001">Fig 1</xref>, the score value of <italic>miRNA</italic>1 (<italic>m</italic><sub>1</sub>) and <italic>disease</italic>1 (<italic>d</italic><sub>1</sub>) is calculated as: 1.0<sup>2.26*1</sup> &lt; <italic>m</italic><sub>1</sub> ↔ <italic>d</italic><sub>1</sub> &gt; + (1.0 * 0.7)<sup>2.26*2</sup> &lt; <italic>m</italic><sub>1</sub> ↔ <italic>d</italic><sub>2</sub> ↔ <italic>d</italic><sub>1</sub> &gt; + (0.8 * 1.0)<sup>2.26*2</sup> &lt; <italic>m</italic><sub>1</sub> ↔ <italic>m</italic><sub>3</sub> ↔ <italic>d</italic><sub>1</sub> &gt; + (0.7 * 1.0 * 0.9)<sup>2.26*3</sup> &lt; <italic>m</italic><sub>1</sub> ↔ <italic>m</italic><sub>2</sub> ↔ <italic>d</italic><sub>3</sub> ↔ <italic>d</italic><sub>1</sub> &gt; ≈ 1.6078. The edge between <italic>d</italic><sub>4</sub> and <italic>d</italic><sub>1</sub> is not taken into consideration, because its weight is less than threshold <bold><italic>T</italic></bold>. The code and data of PBMDA is freely available at <ext-link ext-link-type="uri" xlink:href="http://www.escience.cn/system/file?fileId=84394" xlink:type="simple">http://www.escience.cn/system/file?fileId=84394</ext-link>.</p>
</sec>
<sec id="sec010">
<title>LOOCV and 5-fold CV</title>
<p>To evaluate the predictive performance of PBMDA, we implemented LOOCV and 5-fold CV based on known miRNA-disease associations downloaded from HMDD database [<xref ref-type="bibr" rid="pcbi.1005455.ref021">21</xref>]. LOOCV could be divided into two evaluation frameworks based on the ranking scope (i.e., global LOOCV considers all investigated diseases while local LOOCV only includes a given disease). They both followed the common framework of LOOCV, i.e. each known miRNA-disease association was left in turns served as a test sample and other known miRNA-disease associations were regarded as training samples. Test sample was ranked among the candidate miRNA-disease associations without any known association evidences. The test samples with higher ranks than the specific threshold would be considered as successful predictions. In the framework of 5-fold CV, all known verified miRNA-disease associations were randomly divided into five uncrossed groups, of which one was regarded as testing samples and the other four were used for training in turns. In this paper, we randomly implemented 100 divisions of all known verified miRNA-disease associations to reduce bias brought by sample divisions. The receiver operating characteristic (ROC) curves were drawn for performance evaluation by calculating true positive rate (TPR, sensitivity) and false positive rate (FPR, 1-specificity) based on the varying threshold. Sensitivity indicates the percentage of the positive test samples which are ranked higher than the given threshold; specificity indicates the percentage of candidate samples which are ranked lower than the given threshold. In this way, the ROC curves were plotted based on TPR versus FPR. The areas under ROC curves (AUCs) were also calculated for a numerical evaluation of model performance. AUC = 0.5 denotes a purely random prediction while AUC = 1 denotes a perfect prediction. As a result, the reliable AUCs of 0.9169 and 0.8341 in the frameworks of global and local LOOCV were obtained by PBMDA. Furthermore, the average and the standard deviation of AUC in the framework of 5-fold CV are 0.9172 and 0.0007, respectively. It is anticipated that PBMDA could serve as an effective and robust computational prediction model.</p>
</sec>
</sec>
<sec id="sec011" sec-type="results">
<title>Results</title>
<sec id="sec012">
<title>Performance comparison with other methods</title>
<p>We further compared the prediction performance of PBMDA model with four state-of-the-art computational prediction models (i.e., WBSMDA [<xref ref-type="bibr" rid="pcbi.1005455.ref036">36</xref>], RLSMDA [<xref ref-type="bibr" rid="pcbi.1005455.ref038">38</xref>], HDMP [<xref ref-type="bibr" rid="pcbi.1005455.ref031">31</xref>] and RWRMDA [<xref ref-type="bibr" rid="pcbi.1005455.ref033">33</xref>]). RWRMDA and HDMP are the representational methods in this domain. They were often chosen as benchmarking methods to validate the later developed methods, such as: MIDP [<xref ref-type="bibr" rid="pcbi.1005455.ref035">35</xref>] and Shi’s method [<xref ref-type="bibr" rid="pcbi.1005455.ref036">36</xref>]. RLSMDA was a semi-supervised learning method based on the framework of Regularized Least Squares (RLS) representing a good try in machine learning algorithm. WBSMDA was a newly published method representing the current level of computational prediction models in this domain. The performance comparisons in the framework of global and local LOOCV were shown in <xref ref-type="fig" rid="pcbi.1005455.g002">Fig 2</xref>. As a result, PBMDA, WBSMDA, RLSMDA and HDMP achieved AUCs of 0.9169, 0.8030, 0.8426 and 0.8366 in the framework of global LOOCV, respectively. When implementing the local LOOCV, we also obtain the best prediction performance based on PBMDA with AUC of 0.8341. The other methods (WBSMDA, RWRMDA, HDMP, and RLSMDA) obtained AUCs of 0.8031, 0.7891, 0.7702 and 0.6953, respectively. In addition, 5-fold CV was implemented on PBMDA, WBSMDA, RLSMDA and HDMP with average AUC value of 0.9172+/-0.0007, 0.8185+/-0.0009, 0.8569+/-0.0020 and 0.8342+/-0.0010, respectively, which was observed that PBMDA obtained the best performance based on 5-fold CV. In conclusion, PBMDA significantly improves prediction performance of previous computational models by demonstrating its reliable and robust performance from these evaluation frameworks.</p>
<fig id="pcbi.1005455.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.g002</object-id>
<label>Fig 2</label>
<caption>
<title>The comparison results between PBMDA and other four computational models in terms of global LOOCV and local LOOCV.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec013">
<title>Effects of parameters</title>
<p>For simplicity, the maximum path length <bold><italic>L</italic></bold> and weight threshold <bold><italic>T</italic></bold> were respectively selected 3 and 0.5 for the prediction. It is possible to obtain the better prediction performance by adjusting these parameters values. 5-fold CV was implemented over 100 times for further evaluation. As a result, given <bold><italic>T</italic></bold> = 0.5, the average AUC respectively equals to 0.7726+/-0.0016 (when <bold><italic>L</italic></bold> = 2) and 0.9172+/-0.0007 (when <bold><italic>L</italic></bold> = 3). It seemed that, the performance of our model could be affected by being restrained with the insufficient neighbor length in each path. Because it took too long to run the program, we did not complete the experiment when <bold><italic>L</italic></bold> = 4. It seems that as <bold><italic>L</italic></bold> increases, the computational complexity represents an exponential growth. However, we also implemented 5-fold CV 100 times based on our model and a smaller dataset (HMDD v1.0, 1395 known miRNA-disease associations involved in 271 miRNAs and 137 diseases) for testing performance with increasing <bold><italic>L</italic></bold> (<bold><italic>L</italic></bold> = 2~4) and fixed <bold><italic>T</italic></bold> (<bold><italic>T</italic></bold> = 0.5). As we can see in <xref ref-type="table" rid="pcbi.1005455.t001">Table 1</xref>, the prediction accuracy of proposed model is deceased with the increasing <bold><italic>L</italic></bold> based on a smaller dataset. It is assumed that the increasing <bold><italic>L</italic></bold> tends to cause overfitting problems for a small network dataset. Therefore, it is not necessary to obtain the improvement of prediction accuracy by increasing the path length <bold><italic>L</italic></bold>. We should take the size of a network dataset into consideration when selecting parameter <bold><italic>L</italic></bold>. It seems like that <bold><italic>L</italic></bold> should be generally increased, as the network dataset becomes larger. Nevertheless, it does not need to select a too high numerical value for <bold><italic>L</italic></bold> for avoiding overfitting. Considering the reliable performance of three maximum limited lengths for each path (i.e., <bold><italic>L</italic></bold> = 3), there is no necessity to select <bold><italic>L</italic></bold> = 4 in this study. This setting also helps reduce the run-time of computational model to travel all possible paths.</p>
<table-wrap id="pcbi.1005455.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t001</object-id>
<label>Table 1</label> <caption><title>Five-fold CV experiment results of changing a parameter <italic>L</italic> when <italic>T</italic> = 0.5 based on a smaller dataset (HMDD v1.0).</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center"><italic>L</italic></th>
<th align="center">2</th>
<th align="center">3</th>
<th align="center">4</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">Average AUC</td>
<td align="center">0.9175+/-0.0022</td>
<td align="center">0.8823+/-0.0021</td>
<td align="center">0.8443+/-0.0019</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>We also implemented a series of 5-fold CV experiments with the increasing <bold><italic>T</italic></bold> values to obtain the optimal setting (see <xref ref-type="table" rid="pcbi.1005455.t002">Table 2</xref>). It is showed that, the selection of <bold><italic>T</italic></bold> value cannot greatly affect the accuracy of PBMDA, which demonstrates a strong robustness on this parameter. So we made a better trade-off to set <bold><italic>T</italic></bold> = 0.5.</p>
<table-wrap id="pcbi.1005455.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t002</object-id>
<label>Table 2</label> <caption><title>Five-fold CV experiment results of changing a parameter <italic>T</italic> when <italic>L</italic> = 3.</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center"><italic>T</italic> value</th>
<th align="center">Average AUCs</th>
<th align="center">Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">0.2</td>
<td align="center">0.9174</td>
<td align="center">0.0007</td>
</tr>
<tr>
<td align="center">0.3</td>
<td align="center">0.9174</td>
<td align="center">0.0007</td>
</tr>
<tr>
<td align="center">0.4</td>
<td align="center">0.9173</td>
<td align="center">0.0007</td>
</tr>
<tr>
<td align="center">0.5</td>
<td align="center">0.9172</td>
<td align="center">0.0007</td>
</tr>
<tr>
<td align="center">0.6</td>
<td align="center">0.9168</td>
<td align="center">0.0007</td>
</tr>
<tr>
<td align="center">0.7</td>
<td align="center">0.9158</td>
<td align="center">0.0007</td>
</tr>
<tr>
<td align="center">0.8</td>
<td align="center">0.9138</td>
<td align="center">0.0009</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec014">
<title>Case studies</title>
<p>Many miRNAs in the top rank were predicted to have associations with digestive system and urinary system. It seems that miRNA functional expression is closely related to the dysfunction of both digestive system and urinary system. We attempted to explore their potential relationships and what a role of miRNA plays in disease mechanisms of digestive and urinary system. Esophagus and colon belong to digestive system, while kidney belongs to urinary system. Therefore, to further evaluate the prediction performance of PBMDA, <italic>Esophageal Neoplasms</italic>, <italic>Kidney Neoplasms</italic> and <italic>Colon Neoplasms</italic> were investigated to infer their underlying associated miRNAs. Two independent databases (i.e., dbDEMC [<xref ref-type="bibr" rid="pcbi.1005455.ref040">40</xref>] and miR2Disease [<xref ref-type="bibr" rid="pcbi.1005455.ref022">22</xref>]) were used as benchmark datasets to verify the predictive results. The quantitative statistics demonstrates the reasonability of this benchmarking method (see <xref ref-type="table" rid="pcbi.1005455.t003">Table 3</xref>). Besides, miR2Disease and dbDEMC are commonly utilized to be benchmark datasets in this domain, such as HDMP and MIDP models. It is worthwhile to note that, the predicted miRNA-disease associations were not included in HMDD database, including those highly-ranked disease-related miRNAs listed in Tables <xref ref-type="table" rid="pcbi.1005455.t004">4</xref>–<xref ref-type="table" rid="pcbi.1005455.t007">7</xref>. For the sake of space, this article only mentions these three cancers. Actually, our model can make a successful prediction for almost all of given important diseases. We also present the verification of top-50 prediction list for those important diseases investigated by other previous computational models, such as: prostate neoplasms, breast neoplasms and lung neoplasms in HDMP (see <xref ref-type="table" rid="pcbi.1005455.t008">Table 8</xref> and <xref ref-type="supplementary-material" rid="pcbi.1005455.s005">S5 Table</xref>). Although HMDD database included plentiful of known miRNA-disease associations, there were still many other miRNA-disease associations existing in other two independent benchmark databases, which were not overlapped in HMDD database. So that, we utilized the known miRNA-disease associations (included in HMDD) to prioritize the novel miRNA-disease associations (not included in HMDD), and evaluated the prediction performance of PBMDA by observing how many these novel associations were matched by other two independent benchmark databases.</p>
<table-wrap id="pcbi.1005455.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t003</object-id>
<label>Table 3</label> <caption><title>The quantitative statistics between test dataset (HMDD) and benchmark datasets (miR2Disease and dbDEMC).</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Database</th>
<th align="center">Total associations without repetition<break/><italic>abbr</italic>. A</th>
<th align="center">Redundant associations removed from HMDD<break/><italic>abbr</italic>. B</th>
<th align="center">Remainder associations<break/>(A-B)</th>
<th align="center">Percentage of remainder associations<break/><inline-formula id="pcbi.1005455.e013"><alternatives><graphic id="pcbi.1005455.e013g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005455.e013" xlink:type="simple"/><mml:math display="inline" id="M13"><mml:mfrac><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>−</mml:mo><mml:mi mathvariant="bold-italic">B</mml:mi></mml:mrow><mml:mrow><mml:mn mathvariant="bold">5430</mml:mn></mml:mrow></mml:mfrac><mml:mo>*</mml:mo><mml:mn mathvariant="bold">100</mml:mn><mml:mi mathvariant="bold">%</mml:mi></mml:math></alternatives></inline-formula></th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">HMDD</td>
<td align="center">5430</td>
<td align="center">/</td>
<td align="center">/</td>
<td align="center">/</td>
</tr>
<tr>
<td align="center">miR2Disease</td>
<td align="center">2875</td>
<td align="center">232</td>
<td align="center">2643</td>
<td align="center">48.7%</td>
</tr>
<tr>
<td align="center">dbDEMC</td>
<td align="center">1815</td>
<td align="center">546</td>
<td align="center">1269</td>
<td align="center">23.4%</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<table-wrap id="pcbi.1005455.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t004</object-id>
<label>Table 4</label> <caption><title>PBMDA was applied to Esophageal Neoplasms to predict the potential disease-related miRNAs, and 44 of top-50 predicted miRNAs have been confirmed according to recent experimental literatures.</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="2">Top 1–25</th>
<th align="center" colspan="2">Top 26–50</th>
</tr>
<tr>
<th align="center">miRNA</th>
<th align="center">Evidence</th>
<th align="center">miRNA</th>
<th align="center">Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">hsa-mir-17</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-195</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-125b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-let-7g</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-221</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-124</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-16</td>
<td align="center">dbdemc</td>
<td align="center">hsa-let-7i</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-18a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-125a</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-200b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-24</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-19b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-106b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-1</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-93</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-218</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-30c</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-222</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-199b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-182</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-224</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-let-7d</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-106a</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-29a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-107</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-181a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-127</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-29b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-429</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-146b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-27b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-10b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-103a</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-181b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-96</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-133b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-18b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-9</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-151a</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-let-7e</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-122</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-142</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-135a</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-30a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-302b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-let-7f</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-335</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-7</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-138</td>
<td align="center">unconfirmed</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<table-wrap id="pcbi.1005455.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t005</object-id>
<label>Table 5</label> <caption><title>PBMDA was applied to Kidney Neoplasms to predict the potential disease-related miRNAs, and 44 of top-50 predicted miRNAs have been confirmed according to recent experimental literatures.</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t005g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t005" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="2">Top 1–25</th>
<th align="center" colspan="2">Top 26–50</th>
</tr>
<tr>
<th align="center">miRNA</th>
<th align="center">Evidence</th>
<th align="center">miRNA</th>
<th align="center">Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">hsa-mir-155</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-205</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-145</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-19b</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-146a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-181a</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-126</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-218</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-125b</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-let-7c</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-20a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-222</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-17</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-203</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-34a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-9</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-16</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-34c</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-200b</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-10b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-let-7a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-146b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-221</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-182</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-143</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-375</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-92a</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-let-7d</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-200a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-27a</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-31</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-34b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-18a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-101</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-19a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-181b</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-223</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-106b</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-29a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-142</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-29b</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-29c</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-1</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-195</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-let-7b</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-183</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-210</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-486</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-199a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-196a</td>
<td align="center">dbdemc</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<table-wrap id="pcbi.1005455.t006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t006</object-id>
<label>Table 6</label> <caption><title>PBMDA was applied to Colon Neoplasms to predict the potential disease-related miRNAs, and 45 of top-50 predicted miRNAs have been confirmed according to recent experimental literatures.</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t006g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t006" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="2">Top 1–25</th>
<th align="center" colspan="2">Top 26–50</th>
</tr>
<tr>
<th align="center">miRNA</th>
<th align="center">Evidence</th>
<th align="center">miRNA</th>
<th align="center">Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">hsa-mir-21</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-181a</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-20a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-223</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-155</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-let-7c</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-146a</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-199a</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-18a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-34c</td>
<td align="center">miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-34a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-9</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-143</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-let-7d</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-125b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-15a</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-mir-92a</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-10b</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-19b</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-181b</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-16</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-106b</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-221</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-34b</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-19a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-205</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-let-7a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-200a</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-200c</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-203</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-31</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-27a</td>
<td align="center">miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-200b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-30a</td>
<td align="center">miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-29b</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-133b</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-182</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-101</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-218</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-183</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-222</td>
<td align="center">dbdemc</td>
<td align="center">hsa-let-7e</td>
<td align="center">dbdemc</td>
</tr>
<tr>
<td align="center">hsa-let-7b</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-196a</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-29a</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-let-7f</td>
<td align="center">dbdemc;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-210</td>
<td align="center">dbdemc</td>
<td align="center">hsa-mir-142</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-1</td>
<td align="center">dbdemc;miR2Disease</td>
<td align="center">hsa-mir-148a</td>
<td align="center">dbdemc</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<table-wrap id="pcbi.1005455.t007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t007</object-id>
<label>Table 7</label> <caption><title>Nine out of top-10 predicted obesity-related miRNAs have been manually validated by the published literatures.</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t007g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t007" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">MiRNA</th>
<th align="center">Prediction score</th>
<th align="center">Evidence(PMID)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">hsa-mir-20a</td>
<td align="center">223.20</td>
<td align="center">25014161;19348006</td>
</tr>
<tr>
<td align="center">hsa-mir-155</td>
<td align="center">222.22</td>
<td align="center">23991091</td>
</tr>
<tr>
<td align="center">hsa-mir-145</td>
<td align="center">211.36</td>
<td align="center">22688341</td>
</tr>
<tr>
<td align="center">hsa-mir-34a</td>
<td align="center">210.45</td>
<td align="center">22988100</td>
</tr>
<tr>
<td align="center">hsa-mir-146a</td>
<td align="center">202.54</td>
<td align="center">23396142</td>
</tr>
<tr>
<td align="center">hsa-mir-125b</td>
<td align="center">201.68</td>
<td align="center">23396142</td>
</tr>
<tr>
<td align="center">hsa-mir-92a</td>
<td align="center">194.21</td>
<td align="center">22688341</td>
</tr>
<tr>
<td align="center">hsa-mir-126</td>
<td align="center">184.72</td>
<td align="center">24749062</td>
</tr>
<tr>
<td align="center">hsa-mir-19b</td>
<td align="center">180.86</td>
<td align="center">26658372</td>
</tr>
<tr>
<td align="center">hsa-mir-16</td>
<td align="center">175.44</td>
<td align="center">unconfirmed</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<table-wrap id="pcbi.1005455.t008" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t008</object-id>
<label>Table 8</label> <caption><title>Verification of top-50 prediction list for several important human diseases.</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t008g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t008" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Diseases</th>
<th align="center">The verification of top-50 prediction list</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">Prostate neoplasms</td>
<td align="center">43</td>
</tr>
<tr>
<td align="center">Breast neoplasms</td>
<td align="center">33</td>
</tr>
<tr>
<td align="center">Lung neoplasms</td>
<td align="center">32</td>
</tr>
<tr>
<td align="center">Colon neoplasms</td>
<td align="center">45</td>
</tr>
<tr>
<td align="center">Lymphoma</td>
<td align="center">45</td>
</tr>
<tr>
<td align="center">Hepatocellular cancer</td>
<td align="center">17</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p><italic>Esophageal Neoplasms</italic> is one of the most common digestive carcinomas with poor prognosis. With the growth of the tumor, patients could cause corresponding symptoms, such as difficult or painful swallowing, weight loss and coughing up blood. Cisplatin-based chemotherapy is the main approach for the treatment of <italic>Esophageal Neoplasms</italic> but the chemotherapy response is difficultly detected. Some studies suggested that miRNAs could be considered as effective prognostic biomarkers for <italic>Esophageal Neoplasms</italic>. For examples, <italic>hsa-let-7</italic> can be considered as a prognostic biomarker for measuring the response to chemotherapy. In addition, when a recurrence of disease happens, patients have relatively higher expression of mature <italic>hsa-miR-143</italic> and mature <italic>hsa-miR-145</italic> than normal people. A case study of <italic>Esophageal Neoplasms</italic> was implemented on PBMDA for yielding the most probable related miRNAs (see <xref ref-type="table" rid="pcbi.1005455.t004">Table 4</xref>). As a result, 9 of top-10 and 44 of top-50 candidates were confirmed to have associations with <italic>Esophageal Neoplasms</italic> based on previous experimental literatures. For examples, the overexpression of <italic>hsa-miR-17</italic> (1st in the prediction list) cluster can accelerate the cellular growth in <italic>Esophageal Neoplasms</italic> [<xref ref-type="bibr" rid="pcbi.1005455.ref046">46</xref>]. Previous research showed that <italic>hsa-miR-125b</italic> (2nd in the prediction list) can promote cell proliferation in <italic>Esophageal Neoplasms</italic> by influencing the target transcripts: <italic>CYP24</italic>, <italic>ERBB2</italic> and <italic>ERBB3</italic> [<xref ref-type="bibr" rid="pcbi.1005455.ref047">47</xref>]. Moreover, <italic>hsa-miR-221</italic> (3rd in the prediction list) can be regarded as a useful diagnostic marker for measuring the sensitivity to the treatment of <italic>Esophageal Neoplasms</italic> [<xref ref-type="bibr" rid="pcbi.1005455.ref048">48</xref>].</p>
<p><italic>Kidney Neoplasms</italic> is the most rapidly increasing tumor type in incidence rate, especially among black persons. And more than 80 percent of patients are found to have renal-cell carcinoma (RCC). Recent studies found that patients with RCC usually have overexpression of <italic>miR-34a</italic>, which plays a critical role in slowing the growth of RCC. Besides, <italic>MiRs-141/200c</italic> were considered as the most down-regulated miRNAs in RCC by targeting <italic>ZEB2</italic>, which is a type of transcriptional repressor [<xref ref-type="bibr" rid="pcbi.1005455.ref049">49</xref>,<xref ref-type="bibr" rid="pcbi.1005455.ref050">50</xref>]. In order to identify potential disease-miRNA associations, we implemented the case study of <italic>Kidney Neoplasms</italic>. The existing experimental literatures have demonstrated 9 of top-10 and 44 of top-50 potential miRNA candidates were correctly associated with this important human disease (see <xref ref-type="table" rid="pcbi.1005455.t005">Table 5</xref>). For example, <italic>miR-155</italic> (1st in the prediction list), <italic>miR-126</italic> (4th in the prediction list) and <italic>miR-20a</italic> (5th in the prediction list) were identified to be upregulated in clear-cell type human renal cell carcinoma (ccRCC), relative to normal kidney samples [<xref ref-type="bibr" rid="pcbi.1005455.ref051">51</xref>,<xref ref-type="bibr" rid="pcbi.1005455.ref052">52</xref>]. Furthermore, it was found that <italic>miR-145</italic> (2nd in the prediction list) and <italic>miR-146a</italic> (3rd in the prediction list) with over expression suppress their target mRNA and protein expression of the STAT-1 pathway in kidney tissues [<xref ref-type="bibr" rid="pcbi.1005455.ref053">53</xref>].</p>
<p><italic>Colon Neoplasms</italic> maintains the second leading cause of cancer-related death in the United States [<xref ref-type="bibr" rid="pcbi.1005455.ref054">54</xref>]. Although chemotherapy has important therapeutic value, surgery is still the only curative way for the treatment of <italic>Colon Neoplasms</italic>. There is an urgent need to find potential biomarkers, which have a strong response to the clinical observations. By using in situ hybridization technique, researchers have confirmed that <italic>miR-21</italic> has high expression levels in colonic carcinoma cells [<xref ref-type="bibr" rid="pcbi.1005455.ref055">55</xref>]. What’s more, <italic>let-7</italic> functions as a potential growth suppressor in human colon cancer tumors and cell lines [<xref ref-type="bibr" rid="pcbi.1005455.ref056">56</xref>]. Identifying more miRNAs associated with <italic>Colon Neoplasms</italic> helps accurately evaluate the clinical outcomes. Therefore, we implemented the case study of <italic>Colon Neoplasms</italic> based on PBMDA. In the prediction list, 9 of top-10 and 45 of top-50 predicted miRNAs obtained confirmation of their associations with <italic>Colon Neoplasms</italic> based on recent experimental literatures (see <xref ref-type="table" rid="pcbi.1005455.t006">Table 6</xref>). For examples, preclinical research showed that the expression of <italic>miR-21</italic> (1st in the prediction list) is related to clinicopathologic features of colorectal cancer [<xref ref-type="bibr" rid="pcbi.1005455.ref057">57</xref>]. Experimental studies also found that <italic>miR-20a</italic> (2nd in the prediction list) shows significantly higher expression in colon cancer tissues than normal tissues [<xref ref-type="bibr" rid="pcbi.1005455.ref058">58</xref>]. <italic>MiR-18a</italic> (3rd in the prediction list) is considered as a colon tumor suppressor by targeting on <italic>K-Ras</italic> (mRNA) to influence cell proliferation and anchorage-independent growth [<xref ref-type="bibr" rid="pcbi.1005455.ref059">59</xref>]. What’s more, <italic>miR-34a</italic> (6th in the prediction list) has important potential to be used as potential diagnostic and prognostic biomarker by using its expression at different stages of <italic>Colon Neoplasms</italic> [<xref ref-type="bibr" rid="pcbi.1005455.ref060">60</xref>].</p>
<p>Considering that most cancers are characterized by some extent of genetic and genomic modifications, so the fact that cancers are associated with miRNA dysregulation is perhaps an obvious form of validation, which inspired us to know whether PBMDA can achieve the similar effectiveness for another disease type, such as obesity. Because there is only one entry corresponding to the miRNA-obesity association in both HMDD and the two independent benchmark databases (i.e., dbDEMC [<xref ref-type="bibr" rid="pcbi.1005455.ref040">40</xref>] and miR2Disease [<xref ref-type="bibr" rid="pcbi.1005455.ref022">22</xref>]), we decided to manually validate the top-10 predicted obesity-related miRNAs based on the published literatures. As we can see the validation results from <xref ref-type="table" rid="pcbi.1005455.t007">Table 7</xref>, 9 out of top-10 predicted miRNAs have been demonstrated to be associated with obesity, which demonstrated that PBMDA also work effectively for other diseases.</p>
<p>Because only WBSMDA and PBMDA chose the latest version of HMDD for the prediction, we decided to compare the performance between PBMDA and WBSMDA by observing how many top-50 predicted miRNA-disease associations have been confirmed by dbdemc and miR2Disease databases for these three important diseases. Their validation results were compared in <xref ref-type="table" rid="pcbi.1005455.t009">Table 9</xref>. As we can see from this table, PBMDA perform better than WBSMDA in general.</p>
<table-wrap id="pcbi.1005455.t009" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t009</object-id>
<label>Table 9</label> <caption><title>Performance comparison between PBMDA and WBSMDA in case studies of three important diseases in top-50 prediction list based on the latest version of HMDD (v2.0).</title></caption>
<alternatives>
<graphic id="pcbi.1005455.t009g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t009" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center"/>
<th align="center">Esophageal Neoplasms</th>
<th align="center">Kidney Neoplasms</th>
<th align="center">Colon Neoplasms</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">PBMDA</td>
<td align="center">44</td>
<td align="center">44</td>
<td align="center">45</td>
</tr>
<tr>
<td align="center">WBSMDA</td>
<td align="center">29</td>
<td align="center">39</td>
<td align="center">45</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>Besides, we have also implemented PBMDA on the older version of HMDD (v1.0) for further comparison between PBMDA and another three compared computational models, i.e. HDMP, RWRMDA and RLSMDA. For a fair comparison, we only took those top-50 predicted associations verified by three benchmark databases (i.e. HMDD v2.0, dbDEMC and miR2Disease) into consideration. Namely, those predicted associations additionally verified by extra literatures were not included. Besides, we could only compare performance between PBMDA and other compared models for those given diseases, whose verification was published in their articles, e.g. prostatic, breast and lung neoplasms in HDMP. Based on these comparison results (see <xref ref-type="table" rid="pcbi.1005455.t010">Table 10</xref>), our model generally improves prediction performance for various selected diseases, relative to other compared computational models.</p>
<table-wrap id="pcbi.1005455.t010" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t010</object-id>
<label>Table 10</label> <caption><title>We implemented PBMDA model on the older version of HMDD (v1.0) for further comparison between PBMDA and another three representative computational models, i.e. HDMP, RWRMDA and RLSMDA.</title> <p>For these given diseases, their top-50 prediction lists have been verified by three benchmark databases (i.e. HMDD v2.0, dbDEMC and miR2Disease).</p></caption>
<alternatives>
<graphic id="pcbi.1005455.t010g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t010" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="center"/>
<td align="center">Prostatic neoplasms</td>
<td align="center">Breast neoplasms</td>
<td align="center">Lung neoplasms</td>
</tr>
<tr>
<td align="center">PBMDA</td>
<td align="center">44</td>
<td align="center">48</td>
<td align="center">41</td>
</tr>
<tr>
<td align="center">HDMP</td>
<td align="center">38</td>
<td align="center">43</td>
<td align="center">38</td>
</tr>
<tr>
<td align="center"/>
<td align="center">Breast neoplasms</td>
<td align="center">Colon neoplasms</td>
<td align="center">Lung neoplasms</td>
</tr>
<tr>
<td align="center">PBMDA</td>
<td align="center">48</td>
<td align="center">38</td>
<td align="center">41</td>
</tr>
<tr>
<td align="center">RWRMDA</td>
<td align="center">48</td>
<td align="center">33</td>
<td align="center">43</td>
</tr>
<tr>
<td align="center"/>
<td align="center">Hepatocellular cancer</td>
<td align="center">Colon cancer</td>
<td align="center"/>
</tr>
<tr>
<td align="center">PBMDA</td>
<td align="center">38</td>
<td align="center">38</td>
<td align="center"/>
</tr>
<tr>
<td align="center">RLSMDA</td>
<td align="center">40</td>
<td align="center">36</td>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>To prove the applicability of our model to a new disease (no known associated miRNAs), we selected <italic>Glioblastoma</italic> for further verification. We removed all records about <italic>Glioblastoma</italic> from the known miRNA-disease association network derived from HMDD and that <italic>Glioblastoma</italic> could be regarded as a new disease. We implemented our model for prediction and then the prediction result about <italic>Glioblastoma</italic> was yielded. Similarly, we verified top-50 predicted miRNA-disease associations by HMDD, dbDEMC and miR2Disease (see <xref ref-type="table" rid="pcbi.1005455.t011">Table 11</xref>). Fifteen out of top-20 and 37 out of top-50 predicted miRNAs have been verified to be associated with <italic>Glioblastoma</italic> by HMDD, dbDEMC and miR2Disease. Based on these prediction results, we can safely conclude that PBMDA can still achieve the reliable prediction performance for a new disease. Most importantly, it also demonstrates that our model is indeed applicable to a new disease.</p>
<table-wrap id="pcbi.1005455.t011" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005455.t011</object-id>
<label>Table 11</label> <caption><title>We removed all records about <italic>Glioblastoma</italic> from the known miRNA-disease association network derived from HMDD and implemented our model for prediction.</title> <p>Fifteen out of top-20 and 37 out of top-50 predicted miRNAs have been verified to be associated with <italic>Glioblastoma</italic> by HMDD, miR2Disease and dbDEMC databases.</p></caption>
<alternatives>
<graphic id="pcbi.1005455.t011g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.t011" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="2">Top 1–25</th>
<th align="center" colspan="2">Top 26–50</th>
</tr>
<tr>
<th align="center">miRNA</th>
<th align="center">Evidence</th>
<th align="center">miRNA</th>
<th align="center">Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">hsa-mir-21</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
<td align="center">hsa-mir-574</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-155</td>
<td align="center">HMDD;dbDEMC</td>
<td align="center">hsa-mir-208a</td>
<td align="center">HMDD</td>
</tr>
<tr>
<td align="center">hsa-mir-222</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
<td align="center">hsa-mir-181a</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-221</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
<td align="center">hsa-mir-181c</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-122</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-132</td>
<td align="center">dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-199a</td>
<td align="center">dbDEMC</td>
<td align="center">hsa-mir-214</td>
<td align="center">dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-205</td>
<td align="center">HMDD;dbDEMC</td>
<td align="center">hsa-mir-125b</td>
<td align="center">HMDD;miR2Disease</td>
</tr>
<tr>
<td align="center">hsa-mir-451a</td>
<td align="center">HMDD</td>
<td align="center">hsa-mir-25</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-93</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-182</td>
<td align="center">dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-451</td>
<td align="center">miR2Disease</td>
<td align="center">hsa-mir-181b</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-142</td>
<td align="center">HMDD;dbDEMC</td>
<td align="center">hsa-mir-1</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-206</td>
<td align="center">HMDD;dbDEMC</td>
<td align="center">hsa-mir-9</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-34a</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
<td align="center">hsa-mir-641</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-27a</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-1287</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-210</td>
<td align="center">HMDD;dbDEMC</td>
<td align="center">hsa-mir-1286</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-10b</td>
<td align="center">HMDD;miR2Disease;dbDEMC</td>
<td align="center">hsa-mir-22</td>
<td align="center">HMDD</td>
</tr>
<tr>
<td align="center">hsa-mir-23b</td>
<td align="center">HMDD;miR2Disease</td>
<td align="center">hsa-mir-1290</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-320c</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-432</td>
<td align="center">dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-30b</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-197</td>
<td align="center">miR2Disease;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-27b</td>
<td align="center">HMDD</td>
<td align="center">hsa-mir-19a</td>
<td align="center">HMDD;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-193b</td>
<td align="center">unconfirmed</td>
<td align="center">hsa-mir-34c</td>
<td align="center">dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-16</td>
<td align="center">HMDD;dbDEMC</td>
<td align="center">hsa-mir-106b</td>
<td align="center">unconfirmed</td>
</tr>
<tr>
<td align="center">hsa-mir-15a</td>
<td align="center">HMDD;dbDEMC</td>
<td align="center">hsa-mir-19b</td>
<td align="center">HMDD;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-17</td>
<td align="center">HMDD;dbDEMC</td>
<td align="center">hsa-mir-18a</td>
<td align="center">HMDD;dbDEMC</td>
</tr>
<tr>
<td align="center">hsa-mir-29a</td>
<td align="center">HMDD</td>
<td align="center">hsa-mir-95</td>
<td align="center">HMDD;dbDEMC</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>As a global computational model, PBMDA was also implemented to simultaneously prioritize the potential miRNAs for all investigated diseases. Owing to the limited prior knowledge, some promising disease-related miRNAs have not been validated yet. We therefore listed the top-100 potential associations in <xref ref-type="supplementary-material" rid="pcbi.1005455.s006">S6 Table</xref>.</p>
</sec>
</sec>
<sec id="sec015" sec-type="conclusions">
<title>Discussions</title>
<p>With the great amount of researches, it was found that miRNAs play increasingly significant roles in many physiological processes including complex human diseases. Researchers attempt to identify disease-related miRNAs as valuable biomarkers for clinical measure, diagnosis, prognosis and treatment. The biological experiment-based verification is not only time-consuming but also expensive, which boosts the development of computational predictive models. A novel <underline>P</underline>ath-<underline>B</underline>ased <underline>M</underline>iRNA-<underline>D</underline>isease <underline>A</underline>ssociation (PBMDA) computational prediction model was proposed here by integrating heterogeneous biological networks. PBMDA could construct a heterogeneous graph by padding internal connections, including miRNA-miRNA similarity, disease-disease similarity and known miRNA-disease associations. MiRNA-miRNA similarity and disease-disease similarity are inferred from Gaussian interaction profile kernel similarity for miRNA and disease, miRNA functional similarity network, and disease semantic similarity network. Compared with four state-of-the-art computational models, PBMDA achieved the highest AUCs of 0.9169, 0.8341 and 0.9172+/-0.0007 in the evaluation frameworks of global LOOCV, local LOOCV and 5-fold CV, respectively, demonstrating the most reliable prediction performance. In the case studies of three important human complex diseases, 44, 44, and 45 of top-50 predicted miRNAs of <italic>Esophageal Neoplasms</italic>, <italic>Kidney Neoplasms</italic> and <italic>Colon Neoplasms</italic> have been experimentally supported by the previous experimental literatures, respectively. By manually validating the predicted obesity-related miRNAs based on the published literatures, 9 out of top-10 predicted miRNAs have been demonstrated to be associated with obesity. Furthermore, through the comparison performance between PBMDA and other previous models in case studies, it is anticipated that PBMDA would significantly accelerate the identification of miRNA-disease associations. We are planning to provide a standalone tool or webserver for users in the future. This study is aimed to firstly propose the computational model for the next schedule.</p>
<p>There are several major factors contributing to the high prediction performance of PBMDA. First, reliable biological datasets were utilized to establish an integrated similarity network, which represents three relationships (i.e., miRNA-miRNA similarity, disease-disease similarity, and miRNA-disease associations). Second, as a path-based model, PBMDA can effectively take advantage of topological information implied in the integrated heterogeneous network. Third, PBMDA can be applied for new disease (no known associated miRNAs) and new miRNAs (no known associated diseases), which greatly improves the practicability and reliability of the PBMDA. Depending on the disease semantic similarity and miRNA functional similarity, we can construct the disease-disease and miRNA-miRNA similarity network. Depth-first search algorithm can be used to assign the scores to the paths like: disease<sub>new</sub>↔disease↔miRNA and miRNA<sub>new</sub>↔miRNA↔disease. In this way, the unverified disease-miRNA associations including new diseases and/or new miRNAs also can be prioritized based on their aggregated scores. Fourth, the model of PBMDA can be easily introduced together with other biological information (e.g. various miRNA-related interactions and disease phenotypic similarity [<xref ref-type="bibr" rid="pcbi.1005455.ref061">61</xref>,<xref ref-type="bibr" rid="pcbi.1005455.ref062">62</xref>]) for further improving the quality of the integrated heterogeneous network. Last but not least, PBMDA could simultaneously prioritize candidate miRNAs for all investigated diseases.</p>
<p>There is still a vast potential to boost the prediction performance of PBMDA, which still have some limitations. For examples, the miRNA-disease associations obtained from HMDD database are far from enough, which greatly influences the performance of our approach. The disease semantic similarity and miRNA functional similarity have problem of sparsity, which was remedied by integrating the Gaussian interaction profile kernel similarity inferred from the known miRNA-disease associations. It inevitably did bring the predicted error to the constructed heterogeneous graph. Finally, the distance-decay function in our approach is relatively simple, and it could be reconstructed based on the machine learning methods.</p>
</sec>
<sec id="sec016">
<title>Supporting information</title>
<supplementary-material id="pcbi.1005455.s001" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Known human miRNA-disease associations obtained from HMDD database.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005455.s002" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.s002" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Names of 495 miRNAs involved in known human miRNA-disease associations obtained from HMDD database.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005455.s003" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.s003" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>Names of 383 diseases involved in known human miRNA-disease associations obtained from HMDD database.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005455.s004" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.s004" xlink:type="simple">
<label>S4 Table</label>
<caption>
<title>The constructed miRNA functional similarity score matrix.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005455.s005" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.s005" xlink:type="simple">
<label>S5 Table</label>
<caption>
<title>PBMDA’s top-50 prediction list verified by dbDEMC and miR2Disease databases.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005455.s006" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005455.s006" xlink:type="simple">
<label>S6 Table</label>
<caption>
<title>As a global measure model, PBMDA can simultaneously prioritize all unknown potential related miRNAs for all investigated diseases.</title>
<p>We here publicly released the top-100 potential miRNA-disease associations predicted by PBMDA.</p>
<p>(XLSX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pcbi.1005455.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meister</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Tuschl</surname> <given-names>T</given-names></name> (<year>2004</year>) <article-title>Mechanisms of gene silencing by double-stranded RNA</article-title>. <source>Nature</source> <volume>431</volume>: <fpage>343</fpage>–<lpage>349</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature02873" xlink:type="simple">10.1038/nature02873</ext-link></comment> <object-id pub-id-type="pmid">15372041</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bartel</surname> <given-names>DP</given-names></name> (<year>2004</year>) <article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title>. <source>cell</source> <volume>116</volume>: <fpage>281</fpage>–<lpage>297</lpage>. <object-id pub-id-type="pmid">14744438</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ambros</surname> <given-names>V</given-names></name> (<year>2001</year>) <article-title>microRNAs: tiny regulators with great potential</article-title>. <source>Cell</source> <volume>107</volume>: <fpage>823</fpage>–<lpage>826</lpage>. <object-id pub-id-type="pmid">11779458</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ambros</surname> <given-names>V</given-names></name> (<year>2004</year>) <article-title>The functions of animal microRNAs</article-title>. <source>Nature</source> <volume>431</volume>: <fpage>350</fpage>–<lpage>355</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature02871" xlink:type="simple">10.1038/nature02871</ext-link></comment> <object-id pub-id-type="pmid">15372042</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Feinbaum</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Ambros</surname> <given-names>V</given-names></name> (<year>1993</year>) <article-title>The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14</article-title>. <source>Cell</source> <volume>75</volume>: <fpage>843</fpage>–<lpage>854</lpage>. <object-id pub-id-type="pmid">8252621</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reinhart</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Slack</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Basson</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pasquinelli</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Bettinger</surname> <given-names>JC</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans</article-title>. <source>Nature</source> <volume>403</volume>: <fpage>901</fpage>–<lpage>906</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/35002607" xlink:type="simple">10.1038/35002607</ext-link></comment> <object-id pub-id-type="pmid">10706289</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wightman</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ha</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Ruvkun</surname> <given-names>G</given-names></name> (<year>1993</year>) <article-title>Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans</article-title>. <source>Cell</source> <volume>75</volume>: <fpage>855</fpage>–<lpage>862</lpage>. <object-id pub-id-type="pmid">8252622</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kozomara</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Griffiths-Jones</surname> <given-names>S</given-names></name> (<year>2011</year>) <article-title>miRBase: integrating microRNA annotation and deep-sequencing data</article-title>. <source>Nucleic Acids Res</source> <volume>39</volume>: <fpage>D152</fpage>–<lpage>D157</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkq1027" xlink:type="simple">10.1093/nar/gkq1027</ext-link></comment> <object-id pub-id-type="pmid">21037258</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ambros</surname> <given-names>V</given-names></name> (<year>2003</year>) <article-title>MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing</article-title>. <source>Cell</source> <volume>113</volume>: <fpage>673</fpage>–<lpage>676</lpage>. <object-id pub-id-type="pmid">12809598</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Taganov</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Boldin</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>K-J</given-names></name>, <name name-style="western"><surname>Baltimore</surname> <given-names>D</given-names></name> (<year>2006</year>) <article-title>NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>103</volume>: <fpage>12481</fpage>–<lpage>12486</lpage>.</mixed-citation></ref>
<ref id="pcbi.1005455.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>C-Z</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lodish</surname> <given-names>HF</given-names></name>, <name name-style="western"><surname>Bartel</surname> <given-names>DP</given-names></name> (<year>2004</year>) <article-title>MicroRNAs modulate hematopoietic lineage differentiation</article-title>. <source>Science</source> <volume>303</volume>: <fpage>83</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1091903" xlink:type="simple">10.1126/science.1091903</ext-link></comment> <object-id pub-id-type="pmid">14657504</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Carleton</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Cleary</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Linsley</surname> <given-names>PS</given-names></name> (<year>2007</year>) <article-title>MicroRNAs and cell cycle regulation</article-title>. <source>Cell cycle</source> <volume>6</volume>: <fpage>2127</fpage>–<lpage>2132</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4161/cc.6.17.4641" xlink:type="simple">10.4161/cc.6.17.4641</ext-link></comment> <object-id pub-id-type="pmid">17786041</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Urbich</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kuehbacher</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Dimmeler</surname> <given-names>S</given-names></name> (<year>2008</year>) <article-title>Role of microRNAs in vascular diseases, inflammation, and angiogenesis</article-title>. <source>Cardiovascular Research</source> <volume>79</volume>: <fpage>581</fpage>–<lpage>588</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/cvn156" xlink:type="simple">10.1093/cvr/cvn156</ext-link></comment> <object-id pub-id-type="pmid">18550634</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Petrocca</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Visone</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Onelli</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Shah</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Nicoloso</surname> <given-names>MS</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer</article-title>. <source>Cancer cell</source> <volume>13</volume>: <fpage>272</fpage>–<lpage>286</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccr.2008.02.013" xlink:type="simple">10.1016/j.ccr.2008.02.013</ext-link></comment> <object-id pub-id-type="pmid">18328430</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leung</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Sharp</surname> <given-names>PA</given-names></name> (<year>2010</year>) <article-title>MicroRNA functions in stress responses</article-title>. <source>Molecular cell</source> <volume>40</volume>: <fpage>205</fpage>–<lpage>215</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molcel.2010.09.027" xlink:type="simple">10.1016/j.molcel.2010.09.027</ext-link></comment> <object-id pub-id-type="pmid">20965416</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Teruya-Feldstein</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Weinberg</surname> <given-names>RA</given-names></name> (<year>2007</year>) <article-title>Tumour invasion and metastasis initiated by microRNA-10b in breast cancer</article-title>. <source>Nature</source> <volume>449</volume>: <fpage>682</fpage>–<lpage>688</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature06174" xlink:type="simple">10.1038/nature06174</ext-link></comment> <object-id pub-id-type="pmid">17898713</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sredni</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Bonaldo</surname> <given-names>MdF</given-names></name>, <name name-style="western"><surname>Tomita</surname> <given-names>T</given-names></name> (<year>2011</year>) <article-title>MicroRNA expression profiling for molecular classification of pediatric brain tumors</article-title>. <source>Pediatric blood &amp; cancer</source> <volume>57</volume>: <fpage>183</fpage>–<lpage>184</lpage>.</mixed-citation></ref>
<ref id="pcbi.1005455.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shi</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Sepp-Lorenzino</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Prisco</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Linsley</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Baserga</surname> <given-names>R</given-names></name> (<year>2007</year>) <article-title>Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells</article-title>. <source>Journal of Biological Chemistry</source> <volume>282</volume>: <fpage>32582</fpage>–<lpage>32590</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M702806200" xlink:type="simple">10.1074/jbc.M702806200</ext-link></comment> <object-id pub-id-type="pmid">17827156</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fiedler</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Thum</surname> <given-names>T</given-names></name> (<year>2012</year>) <article-title>Cardiovascular Importance of the MicroRNA‐23/27/24 Family</article-title>. <source>Microcirculation</source> <volume>19</volume>: <fpage>208</fpage>–<lpage>214</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1549-8719.2011.00153.x" xlink:type="simple">10.1111/j.1549-8719.2011.00153.x</ext-link></comment> <object-id pub-id-type="pmid">22136461</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weidhaas</surname> <given-names>J</given-names></name> (<year>2010</year>) <article-title>Using microRNAs to understand cancer biology</article-title>. <source>The Lancet Oncology</source> <volume>11</volume>: <fpage>106</fpage>–<lpage>107</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(09)70386-9" xlink:type="simple">10.1016/S1470-2045(09)70386-9</ext-link></comment> <object-id pub-id-type="pmid">20022811</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Qiu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Tu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Geng</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>J</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>HMDD v2.0: a database for experimentally supported human microRNA and disease associations</article-title>. <source>Nucleic acids research</source> <volume>42</volume>: <fpage>D1070</fpage>–<lpage>1074</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkt1023" xlink:type="simple">10.1093/nar/gkt1023</ext-link></comment> <object-id pub-id-type="pmid">24194601</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jiang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hao</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Juan</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Teng</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>miR2Disease: a manually curated database for microRNA deregulation in human disease</article-title>. <source>Nucleic acids research</source> <volume>37</volume>: <fpage>D98</fpage>–<lpage>D104</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkn714" xlink:type="simple">10.1093/nar/gkn714</ext-link></comment> <object-id pub-id-type="pmid">18927107</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name> (<year>2016</year>) <article-title>miREFRWR: a novel disease-related microRNA-environmental factor interactions prediction method</article-title>. <source>Mol Biosyst</source> <volume>12</volume>: <fpage>624</fpage>–<lpage>633</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1039/c5mb00697j" xlink:type="simple">10.1039/c5mb00697j</ext-link></comment> <object-id pub-id-type="pmid">26689259</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>Z-H</given-names></name> (<year>2016</year>) <article-title>Long non-coding RNAs and complex diseases: from experimental results to computational models</article-title>. <source>Briefings in Bioinformatics</source>: <fpage>bbw060</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bib/bbw060" xlink:type="simple">10.1093/bib/bbw060</ext-link></comment> <object-id pub-id-type="pmid">27345524</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name> (<year>2015</year>) <article-title>KATZLDA: KATZ measure for the lncRNA-disease association prediction</article-title>. <source>Sci Rep</source> <volume>5</volume>: <fpage>16840</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep16840" xlink:type="simple">10.1038/srep16840</ext-link></comment> <object-id pub-id-type="pmid">26577439</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>K</given-names></name> (<year>2016</year>) <article-title>FMLNCSIM: fuzzy measure-based lncRNA functional similarity calculation model</article-title>. <source>Oncotarget</source> <volume>7</volume>: <fpage>45948</fpage>–<lpage>45958</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.18632/oncotarget.10008" xlink:type="simple">10.18632/oncotarget.10008</ext-link></comment> <object-id pub-id-type="pmid">27322210</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>MX</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>QH</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>GY</given-names></name> (<year>2012</year>) <article-title>Prediction of Disease-Related Interactions between MicroRNAs and Environmental Factors Based on a Semi-Supervised Classifier</article-title>. <source>PLoS One</source> <volume>7</volume>: <fpage>e43425</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0043425" xlink:type="simple">10.1371/journal.pone.0043425</ext-link></comment> <object-id pub-id-type="pmid">22937049</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name> (<year>2015</year>) <article-title>Predicting lncRNA-disease associations and constructing lncRNA functional similarity network based on the information of miRNA</article-title>. <source>Sci Rep</source> <volume>5</volume>: <fpage>13186</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep13186" xlink:type="simple">10.1038/srep13186</ext-link></comment> <object-id pub-id-type="pmid">26278472</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>G-Y</given-names></name> (<year>2013</year>) <article-title>Novel human lncRNA–disease association inference based on lncRNA expression profiles</article-title>. <source>Bioinformatics</source> <volume>29</volume>: <fpage>2617</fpage>–<lpage>2624</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btt426" xlink:type="simple">10.1093/bioinformatics/btt426</ext-link></comment> <object-id pub-id-type="pmid">24002109</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jiang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Hao</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Juan</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Prioritization of disease microRNAs through a human phenome-microRNAome network</article-title>. <source>BMC systems biology</source> <volume>4</volume>: <fpage>1</fpage>.</mixed-citation></ref>
<ref id="pcbi.1005455.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xuan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Prediction of microRNAs associated with human diseases based on weighted k most similar neighbors</article-title>. <source>PloS one</source> <volume>8</volume>: <fpage>e70204</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0070204" xlink:type="simple">10.1371/journal.pone.0070204</ext-link></comment> <object-id pub-id-type="pmid">23950912</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mork</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pletscher-Frankild</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Palleja Caro</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gorodkin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jensen</surname> <given-names>LJ</given-names></name> (<year>2014</year>) <article-title>Protein-driven inference of miRNA-disease associations</article-title>. <source>Bioinformatics</source> <volume>30</volume>: <fpage>392</fpage>–<lpage>397</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btt677" xlink:type="simple">10.1093/bioinformatics/btt677</ext-link></comment> <object-id pub-id-type="pmid">24273243</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>M-X</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>G-Y</given-names></name> (<year>2012</year>) <article-title>RWRMDA: predicting novel human microRNA–disease associations</article-title>. <source>Molecular BioSystems</source> <volume>8</volume>: <fpage>2792</fpage>–<lpage>2798</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1039/c2mb25180a" xlink:type="simple">10.1039/c2mb25180a</ext-link></comment> <object-id pub-id-type="pmid">22875290</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xuan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Prediction of potential disease-associated microRNAs based on random walk</article-title>. <source>Bioinformatics</source> <volume>31</volume>: <fpage>1805</fpage>–<lpage>1815</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btv039" xlink:type="simple">10.1093/bioinformatics/btv039</ext-link></comment> <object-id pub-id-type="pmid">25618864</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Walking the interactome to identify human miRNA-disease associations through the functional link between miRNA targets and disease genes</article-title>. <source>BMC systems biology</source> <volume>7</volume>: <fpage>101</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1752-0509-7-101" xlink:type="simple">10.1186/1752-0509-7-101</ext-link></comment> <object-id pub-id-type="pmid">24103777</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>ZH</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>L</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>WBSMDA: Within and Between Score for MiRNA-Disease Association prediction</article-title>. <source>Sci Rep</source> <volume>6</volume>: <fpage>21106</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep21106" xlink:type="simple">10.1038/srep21106</ext-link></comment> <object-id pub-id-type="pmid">26880032</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>C-X</given-names></name>, <name name-style="western"><surname>Lv</surname> <given-names>J-Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y-S</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Prioritizing candidate disease miRNAs by topological features in the mirna target–dysregulated network: Case study of prostate cancer</article-title>. <source>Molecular cancer therapeutics</source> <volume>10</volume>: <fpage>1857</fpage>–<lpage>1866</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1535-7163.MCT-11-0055" xlink:type="simple">10.1158/1535-7163.MCT-11-0055</ext-link></comment> <object-id pub-id-type="pmid">21768329</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>GY</given-names></name> (<year>2014</year>) <article-title>Semi-supervised learning for potential human microRNA-disease associations inference</article-title>. <source>Sci Rep</source> <volume>4</volume>: <fpage>5501</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep05501" xlink:type="simple">10.1038/srep05501</ext-link></comment> <object-id pub-id-type="pmid">24975600</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>L</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>RBMMMDA: predicting multiple types of disease-microRNA associations</article-title>. <source>Sci Rep</source> <volume>5</volume>: <fpage>13877</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep13877" xlink:type="simple">10.1038/srep13877</ext-link></comment> <object-id pub-id-type="pmid">26347258</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Ren</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>G</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>dbDEMC: a database of differentially expressed miRNAs in human cancers</article-title>. <source>BMC genomics</source> <volume>11</volume>: <fpage>S5</fpage>.</mixed-citation></ref>
<ref id="pcbi.1005455.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>Q</given-names></name> (<year>2010</year>) <article-title>Inferring the human microRNA functional similarity and functional network based on microRNA-associated diseases</article-title>. <source>Bioinformatics</source> <volume>26</volume>: <fpage>1644</fpage>–<lpage>1650</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btq241" xlink:type="simple">10.1093/bioinformatics/btq241</ext-link></comment> <object-id pub-id-type="pmid">20439255</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gong</surname> <given-names>D</given-names></name> (<year>2016</year>) <article-title>IRWRLDA: Improved Random Walk with Restart for LncRNA-Disease Association prediction</article-title>. <source>Oncotarget</source> <volume>7</volume>: <fpage>57919</fpage>–<lpage>57931</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.18632/oncotarget.11141" xlink:type="simple">10.18632/oncotarget.11141</ext-link></comment> <object-id pub-id-type="pmid">27517318</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>K</given-names></name> (<year>2016</year>) <article-title>ILNCSIM: improved lncRNA functional similarity calculation model</article-title>. <source>Oncotarget</source> <volume>7</volume>: <fpage>25902</fpage>–<lpage>25914</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.18632/oncotarget.8296" xlink:type="simple">10.18632/oncotarget.8296</ext-link></comment> <object-id pub-id-type="pmid">27028993</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Laarhoven</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nabuurs</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Marchiori</surname> <given-names>E</given-names></name> (<year>2011</year>) <article-title>Gaussian interaction profile kernels for predicting drug-target interaction</article-title>. <source>Bioinformatics</source> <volume>27</volume>: <fpage>3036</fpage>–<lpage>3043</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btr500" xlink:type="simple">10.1093/bioinformatics/btr500</ext-link></comment> <object-id pub-id-type="pmid">21893517</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ba-Alawi</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Soufan</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Essack</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kalnis</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Bajic</surname> <given-names>VB</given-names></name> (<year>2016</year>) <article-title>DASPfind: new efficient method to predict drug–target interactions</article-title>. <source>Journal of Cheminformatics</source> <volume>8</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</mixed-citation></ref>
<ref id="pcbi.1005455.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>X-L</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>Y-H</given-names></name>, <name name-style="western"><surname>Feng</surname> <given-names>J-G</given-names></name>, <name name-style="western"><surname>Su</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>P-C</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic indicators in esophageal squamous cell carcinoma</article-title>. <source>The Annals of thoracic surgery</source> <volume>97</volume>: <fpage>1037</fpage>–<lpage>1045</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.athoracsur.2013.10.042" xlink:type="simple">10.1016/j.athoracsur.2013.10.042</ext-link></comment> <object-id pub-id-type="pmid">24360091</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kan</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Meltzer</surname> <given-names>SJ</given-names></name> (<year>2009</year>) <article-title>MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma</article-title>. <source>Current opinion in pharmacology</source> <volume>9</volume>: <fpage>727</fpage>–<lpage>732</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.coph.2009.08.009" xlink:type="simple">10.1016/j.coph.2009.08.009</ext-link></comment> <object-id pub-id-type="pmid">19773200</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Okamoto</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Miyoshi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Murawaki</surname> <given-names>Y</given-names></name> (<year>2013</year>) <article-title>miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells</article-title>. <source>PLoS One</source> <volume>8</volume>: <fpage>e77623</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0077623" xlink:type="simple">10.1371/journal.pone.0077623</ext-link></comment> <object-id pub-id-type="pmid">24147037</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chow</surname> <given-names>W-H</given-names></name>, <name name-style="western"><surname>Gridley</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Fraumeni</surname> <given-names>JF</given-names> <suffix>Jr</suffix></name>, <name name-style="western"><surname>Järvholm</surname> <given-names>B</given-names></name> (<year>2000</year>) <article-title>Obesity, hypertension, and the risk of kidney cancer in men</article-title>. <source>New England Journal of Medicine</source> <volume>343</volume>: <fpage>1305</fpage>–<lpage>1311</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJM200011023431804" xlink:type="simple">10.1056/NEJM200011023431804</ext-link></comment> <object-id pub-id-type="pmid">11058675</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Catto</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Alcaraz</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bjartell</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>RDV</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>CP</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>MicroRNA in prostate, bladder, and kidney cancer: a systematic review</article-title>. <source>European urology</source> <volume>59</volume>: <fpage>671</fpage>–<lpage>681</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.eururo.2011.01.044" xlink:type="simple">10.1016/j.eururo.2011.01.044</ext-link></comment> <object-id pub-id-type="pmid">21296484</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Juan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Alexe</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Antes</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Madabhushi</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Identification of a microRNA panel for clear-cell kidney cancer</article-title>. <source>Urology</source> <volume>75</volume>: <fpage>835</fpage>–<lpage>841</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.urology.2009.10.033" xlink:type="simple">10.1016/j.urology.2009.10.033</ext-link></comment> <object-id pub-id-type="pmid">20035975</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tsz-fung</surname> <given-names>FC</given-names></name>, <name name-style="western"><surname>Youssef</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Lianidou</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Romaschin</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Honey</surname> <given-names>RJ</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis</article-title>. <source>Clinical biochemistry</source> <volume>43</volume>: <fpage>150</fpage>–<lpage>158</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clinbiochem.2009.07.020" xlink:type="simple">10.1016/j.clinbiochem.2009.07.020</ext-link></comment> <object-id pub-id-type="pmid">19646430</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lu</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>NS</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>KY</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Decreased microRNA (miR)‐145 and increased miR‐224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis</article-title>. <source>Clinical &amp; Experimental Immunology</source> <volume>171</volume>: <fpage>91</fpage>–<lpage>99</lpage>.</mixed-citation></ref>
<ref id="pcbi.1005455.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O’Brien</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Pollett</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gallinger</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dick</surname> <given-names>JE</given-names></name> (<year>2007</year>) <article-title>A human colon cancer cell capable of initiating tumour growth in immunodeficient mice</article-title>. <source>Nature</source> <volume>445</volume>: <fpage>106</fpage>–<lpage>110</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature05372" xlink:type="simple">10.1038/nature05372</ext-link></comment> <object-id pub-id-type="pmid">17122772</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schetter</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Sohn</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Zanetti</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Bowman</surname> <given-names>ED</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma</article-title>. <source>Jama</source> <volume>299</volume>: <fpage>425</fpage>–<lpage>436</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.299.4.425" xlink:type="simple">10.1001/jama.299.4.425</ext-link></comment> <object-id pub-id-type="pmid">18230780</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Akao</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Nakagawa</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Naoe</surname> <given-names>T</given-names></name> (<year>2006</year>) <article-title>let-7 microRNA functions as a potential growth suppressor in human colon cancer cells</article-title>. <source>Biological and Pharmaceutical Bulletin</source> <volume>29</volume>: <fpage>903</fpage>–<lpage>906</lpage>. <object-id pub-id-type="pmid">16651716</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Slaby</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Svoboda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fabian</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Smerdova</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Knoflickova</surname> <given-names>D</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer</article-title>. <source>Oncology</source> <volume>72</volume>: <fpage>397</fpage>–<lpage>402</lpage>.</mixed-citation></ref>
<ref id="pcbi.1005455.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Motoyama</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Inoue</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Takatsuno</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Mimori</surname> <given-names>K</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Over-and under-expressed microRNAs in human colorectal cancer</article-title>. <source>International journal of oncology</source> <volume>34</volume>: <fpage>1069</fpage>. <object-id pub-id-type="pmid">19287964</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tsang</surname> <given-names>WP</given-names></name>, <name name-style="western"><surname>Kwok</surname> <given-names>TT</given-names></name> (<year>2009</year>) <article-title>The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras</article-title>. <source>Carcinogenesis</source> <volume>30</volume>: <fpage>953</fpage>–<lpage>959</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/carcin/bgp094" xlink:type="simple">10.1093/carcin/bgp094</ext-link></comment> <object-id pub-id-type="pmid">19372139</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arndt</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Dossey</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Cullen</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Druker</surname> <given-names>R</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer</article-title>. <source>BMC cancer</source> <volume>9</volume>: <fpage>1</fpage>.</mixed-citation></ref>
<ref id="pcbi.1005455.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>Y-A</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>Z-H</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Luo</surname> <given-names>X</given-names></name> (<year>2016</year>) <article-title>Sequence-based prediction of protein-protein interactions using weighted sparse representation model combined with global encoding</article-title>. <source>BMC bioinformatics</source> <volume>17</volume>: <fpage>184</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12859-016-1035-4" xlink:type="simple">10.1186/s12859-016-1035-4</ext-link></comment> <object-id pub-id-type="pmid">27112932</object-id></mixed-citation></ref>
<ref id="pcbi.1005455.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>Z-H</given-names></name>, <name name-style="western"><surname>Ming</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Detection of interactions between proteins through rotation forest and local phase quantization descriptors</article-title>. <source>International journal of molecular sciences</source> <volume>17</volume>: <fpage>21</fpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>